Sample size calculation
The primary endpoint of this study was the proportion of patients with elevated hsTnI more than the cut-off value (hsTnI > 15.6 ng/L) at the final cycle or 2-week after doxorubicin treatment. From previous study, the incidence of hsTnI elevation post doxorubicin therapy was 41.6%